tirzepatide weight loss efficacy and safety of for treatment of overweight or obesity. A systematic review and meta-analysis JAMA Study comparing Semaglutide and

Patients typically experience a reduction of 10-15% of their initial body weight, with the potential to reach up to 20-25-30% when combined with lifestyle changes

Trial data can help patients understand general medication trends, but a physician must interpret that information in the context of the individual patients health history, side-effect risk, current medications, and long-term goals

Cognitive function either improved or remained stable

The decision to use metformin should involve shared decision-making between patient and provider, considering individual circumstances and preferences

Important safety warnings include risk of pancreatitis (seek urgent medical attention for severe, persistent abdominal pain with or without vomiting), gallbladder disease, dehydration from persistent vomiting or diarrhoea, and potential worsening of diabetic retinopathy with rapid improvement in blood glucose